U.S. Markets closed

Enanta Pharmaceuticals, which is developing its own COVID-19 antiviral, says Pfizer infringed on a patent with Paxlovid

·2 min read
Enanta Pharmaceuticals, which is developing its own COVID-19 antiviral, says Pfizer infringed on a patent with Paxlovid
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Enanta Pharmaceuticals (ENTA) filed a lawsuit against Pfizer (PFE) over Paxlovid, alleging that the COVID-19 antiviral expected to bring in $22 billion in sales this year is based on a patent first filed by Enanta scientists. The suit, which was filed Tuesday in U.S. District Court in Massachusetts, alleges that Enanta filed an application with the U.S. Patent and Trademark Office “describing coronavirus protease inhibitors invented by Enanta scientists” in July 2020. Pfizer’s patent for Paxlovid appears to have been filed three months later, and Enanta’s patent “does appear to cover the chemical space Paxlovid is in,” RBC Capital Markets analyst Brian Abrahams told investors this week.